Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data WINDTREE THERAPEUTICS INC /DE/ files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
0.99
2.04
1.49
1.79
0.2
Cost of revenue
0.93
Gross profit
0.06
Research and development
28.9
31.7
17.4
10.6
12.7
15.4
17.8
11.1
8.34
16.3
Selling, general and administrative
11
8.37
6.66
7.42
12.4
14.9
14.5
10.8
9.2
8.74
Operating expenses
40.8
40.1
24
18
25.1
30.3
77.3
41.3
20.6
26.1
Operating income
-39.8
-38
-22.5
-16.2
-24.9
-30.3
-77.3
-41.3
-20.6
-26.1
Interest expense
4.58
2.52
1.86
1.41
0.5
0.13
0.11
0.05
0.05
0.24
Interest income
0
0.02
0.01
0.02
0.15
0.12
0.09
0.11
0.33
0.07
Other non-operating income
-16.2
-1.68
4.1
-4.34
-2.58
-2.25
-0.34
0.76
0.31
24.3
Pre-tax income
-32.6
-77.6
-40.6
-20.3
-1.79
Income tax
0
0
-9.99
-1.37
0
-0.01
Net income
-55.2
-39.5
-18.4
-20.5
-27.5
-32.6
-67.6
-39.2
-20.3
-1.79
EBITDA
-39.1
-37.8
-22.4
-16
-24.7
-30.1
-77.1
-40.8
-20.5
-26.1
EPS, basic
-7,186.00
-4,269.00
-21,739.00
-6,970.00
-2,260.00
-1,873.00
-123,050.00
-56,041.00
-4,719.00
-104.35
EPS, diluted
-7,186.00
-4,269.00
-21,739.00
-6,970.00
-2,260.00
-1,873.00
-2,458.00
-56,041.00
-4,719.00
-104.35
Shares, basic (weighted)
0.01
0.01
0
0
0.01
0.02
0
0
4.3
52.6
Shares, diluted (weighted)
0.01
0.01
0
0
0.01
0.02
0.03
0
4.3
52.6
Balance sheet
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
38.7
5.59
1.82
11.2
22.6
16.9
22.3
6.17
4.32
1.78
Short-term investments
14
Inventory
0
Other current assets
0.36
0.51
0.42
0.51
1.28
1.19
1.14
1.21
1.06
0.8
Total current assets
40.8
7.19
2.24
25.7
23.9
18.1
23.5
7.38
5.38
2.57
Property, plant and equipment
1.04
1.05
0.89
0.8
0.8
0.92
1.01
0.26
0.18
0.11
Lease right-of-use assets
1.39
0.92
2.38
1.85
1.44
1.05
Goodwill
15.7
15.7
15.7
15.7
3.06
0
Intangible assets
77.1
77.1
77.1
17
9.7
Total assets
44.4
9.7
3.35
119
119
113
74.8
38
32.4
27.9
Accounts payable
0.37
1.81
2.32
3.42
1.71
1.16
0.69
0.25
0.81
1.88
Accrued liabilities
7.2
7.61
4.13
6.47
3.23
3.81
3.41
1.55
1.62
1.71
Deferred revenue
0
0.88
0.2
Short-term debt
0
7.97
Total current liabilities
11.1
13.4
11.8
20.6
7.82
6.13
4.92
2.46
4
5.72
Long-term debt
25
25
Lease liabilities
0.79
0.2
2.07
1.62
1.16
0.65
Other non-current liabilities
0.04
0.14
0.1
0.18
2.8
3.8
3.8
3.8
3.8
Total liabilities
36.1
38.5
27.3
51.3
44
43.3
32.9
27.9
29
14.7
Total debt
25
25
Paid-in capital
590
593
616
729
763
790
830
838
851
860
Retained earnings
-579
-619
-637
-658
-685
-718
-785
-825
-845
-847
Treasury stock
-3.05
-3.05
-3.05
-3.05
-3.05
-3.05
-3.05
-3.05
-3.05
-3.05
Other comprehensive income
0
Shareholders' equity
8.27
-28.8
-23.9
68.1
74.9
69.6
41.9
10
3.39
10
Total equity
8.27
-28.8
-23.9
68.1
74.9
69.6
41.9
10
3.39
10
Total liabilities and equity
44.4
9.7
3.35
119
119
113
74.8
38
32.4
27.9
Shares outstanding
0.01
0
0
0.04
0.02
0.02
0
0
0.01
0.26
Cash flow statement
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-55.2
-39.5
-18.4
-20.5
-27.5
-32.6
-67.6
-39.2
-20.3
-1.79
Depreciation and amortization
0.71
0.26
0.19
0.16
0.2
0.17
0.19
0.53
0.08
0.08
Stock-based compensation
1.7
1.42
1.56
0.96
6.72
5.68
7.24
3.09
1.28
0.46
Deferred income tax
0
-9.99
-1.37
0
-0.21
Change in receivables
0
Change in inventory
0.2
Change in payables
0.02
1.44
2.43
1
-2.47
-0.55
-0.47
-0.44
0.56
1.07
Cash from operations
-33.5
-33.6
-21
-15.8
-24.7
-25.3
-23.7
-19.5
-13.4
-15.4
Capital expenditures
-0.46
-0.28
-0.02
-0.19
-0.29
-0.28
-0.01
-0.02
-0.01
Purchases of investments
-14
Sales and maturities of investments
14
Cash from investing
-0.19
-0.25
-0.02
-13.7
13.8
-0.29
-0.28
0.2
-0.02
-0.01
Debt issued
0.55
0
Debt repaid
-5
-2.5
-0.55
0
Stock issued
0.71
1.04
0
4.84
4.25
0.76
1.37
Dividends paid
0
-0.66
Cash from financing
27.7
0.71
17.3
38.7
21.8
20
29.4
3.08
11.6
12.7
Exchange rate effect
0.09
0.47
Net change in cash
-5.99
-33.1
-3.77
9.32
11.4
-5.65
5.42
-16.2
-1.86
-2.68
Free cash flow
-34
-33.9
-21.1
-24.9
-25.6
-23.9
-19.5
-13.5
-15.4
Interest paid
1.47
0.28
1.09
0.29
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2025; growth uses fiscal years. Valuation uses the share price of $0.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-250.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
194.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-38.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-33.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-14.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-28.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-25.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1,123.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1,141.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
433.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.33x
Current assets / current liabilities.
Quick ratio
0.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.57
Cash from operations / diluted weighted shares.
Book value per share
-$0.35
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-395,471.0%
Net income / market cap (the inverse of P/E).
Dividend yield
3,955.0%
Dividends paid over the period / market cap.
Shareholder yield
3,955.0%
(Dividends paid + share buybacks) / market cap.
Was WINDTREE THERAPEUTICS INC /DE/ profitable in fiscal 2024?
No. It reported a net loss of $1.8M.
How much free cash flow did WINDTREE THERAPEUTICS INC /DE/ generate in fiscal 2024?
Cash from operations of $15.4M minus capital expenditures of $12.0K left free cash flow of -$15.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.